1. Early-Stage Business Risks

• The Company is in the seed stage with limited operating history, making it difficult to predict future performance.

• We have not generated revenue and may not achieve profitability for several years, if at all.
  
  

2. Regulatory Risks

• Our product candidates are subject to extensive regulation by agencies such as the U.S. Food and Drug Administration (FDA) or equivalent authorities in other jurisdictions. There is no guarantee that our products will receive regulatory approval.

• Delays or failures in clinical trials or regulatory processes could significantly impact our business.
  
  

3. Research and Development Risks

• Pharmaceutical research and development is inherently uncertain. Our product candidates may fail to demonstrate safety or efficacy, or may not progress beyond preclinical or clinical stages.

• We rely on third-party partners, such as contract research organizations, which may not perform as expected.
  
  

4. Financial Risks

• The Company will require significant additional capital to fund operations, and there is no assurance that future funding will be available on favorable terms, or at all.

• Investors may face dilution if additional shares are issued in future funding rounds.
  
  

5. Market and Competitive Risks

• The pharmaceutical industry is highly competitive. Established companies with greater resources may develop similar or superior products.

• Market acceptance of our products, if approved, is uncertain and depends on factors beyond our control.
  
  

6. Intellectual Property Risks

• Our success depends on our ability to secure and maintain patents and other intellectual property protections. There is no guarantee that our intellectual property will be enforceable or sufficient to protect our innovations.

• We may face challenges or disputes regarding intellectual property rights, which could be costly and time-consuming.
  
  

7. Data Collection and Privacy

• The Company collects minimal data, limited to IP addresses from website visitors, as described in our Privacy Policy. While we implement reasonable security measures, data breaches or misuse could expose us to liability or reputational harm.
  
  

8. Management and Operational Risks

• Our success depends on the expertise and performance of our management team and key personnel. The loss of key personnel could adversely affect our operations.

• We may face challenges in scaling operations or managing growth effectively.

Financial Information

As a seed-stage company, [Your Startup Name] has limited financial history. Detailed financial statements are available to qualified investors upon request, subject to confidentiality agreements. Key points include:

• The Company has raised [insert seed funding amount, if applicable] in seed capital to date.

• Funds from the Series A round will be used for [briefly describe use of proceeds, e.g., advancing preclinical research, hiring key personnel, or expanding laboratory facilities].

• The Company expects to incur significant expenses related to research and development, with no immediate revenue.
  
  

Data Practices

As noted in our Privacy Policy, we collect only IP addresses from website visitors for purposes such as website functionality, security, and anonymized analytics. We do not collect or process other personal data unless voluntarily provided (e.g., through direct communication). Investors should review our Privacy Policy for details on our data practices.

Forward-Looking Statements

This Disclosure Statement contains forward-looking statements about the Company’s plans, objectives, and expected outcomes. These statements are based on current assumptions and are subject to risks and uncertainties, including those listed above. Actual results may differ materially from those projected.

Confidentiality

This Disclosure Statement is confidential and intended solely for prospective investors evaluating participation in the Series A round. It may not be reproduced, distributed, or disclosed without the Company’s prior written consent.

Contact Information

For additional information or to request offering documents, please contact:

TBT Pharma, Inc

info@tbtpharma.com

Disclaimer: This Disclosure Statement does not constitute an offer to sell or a solicitation of an offer to buy securities. Any such offer will be made only through definitive offering documents in compliance with applicable securities laws. Investors are urged to carefully review all offering materials and conduct their own due diligence.